Loading
Cholangiocarcinoma and Gallbladder Cancer Studies / Gastric Cancer Management and Outcomes · Journal article
Frontiers in Oncology · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-patient case report describing clinical response of HER2-positive metastatic gallbladder adenocarcinoma to trastuzumab emtansine combined with sintilimab, followed by surgical resection and 13 months disease-free survival. The report is preliminary evidence that anti-HER2 therapy may warrant investigation in HER2-positive biliary tract carcinoma, but cannot establish efficacy without controlled trials.
Case report. 46-year-old male with HER2-positive metastatic gallbladder adenocarcinoma; initial treatment with gemcitabine, oxaliplatin, lenvatinib, and sintilimab achieved stable disease; HER2 mutation confirmed by next-generation sequencing.. Intervention: Trastuzumab emtansine in combination with sintilimab (2 cycles before surgical resection); followed by radical cholecystectomy..
46-year-old male with HER2-positive metastatic gallbladder adenocarcinoma achieved lesion size reduction after 2 cycles of trastuzumab emtansine plus sintilimab Patient underwent radical cholecystectomy following treatment Disease-free survival of 13 months documented after surgery
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case suggests anti-HER2 therapy may be a potential treatment option for HER2-positive gallbladder cancer, but clinicians should recognize this is a single favorable outcome and not a basis for routine practice change. Further controlled trials are needed to establish efficacy and safety.
A single case report with a favorable outcome in HER2-positive gallbladder cancer treated with trastuzumab emtansine; raises a hypothesis for future investigation but lacks comparative design, control, or replication.
As stated by the source record.
Quoted from the source exactly as published.
This case suggests anti-HER2 therapy may be a potential treatment option for HER2-positive gallbladder cancer, but clinicians should recognize this is a single favorable outcome and not a basis for routine practice change. Further controlled trials are needed to establish efficacy and safety.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The incidence of biliary tract carcinoma (BTC) is gradually increasing, particularly in Asia where it is most common. Compared with other tumors, it has a low incidence but high mortality and is detected at an advanced stage. Metastatic BTCs have fewer options for systemic therapy and limited treatment options beyond symptomatic therapy for patients who have progressed on first-line therapy. There is therefore a need to explore a biomarker-guided personalized treatment approach. This report describes the case of a 46-year-old middle-aged man with human epidermal growth factor receptor 2 (HER2)-positive metastatic gallbladder adenocarcinoma who was treated preoperatively with two cycles of gemcitabine, oxaliplatin, lenvatinib, and sintilimab; the best objective response was stable disease. Subsequent next-generation sequencing showed positive HER2 gene mutation and the patient was treated with trastuzumab emtansine in combination with sintilimab. After 2 cycles, the lesion was reduced in size and surgical resection was achieved, and the patient underwent radical cholecystectomy for gallbladder cancer (GBC), with a disease-free survival of 13 months after surgery. This case demonstrates the efficacy of trastuzumab emtansine in the treatment of locally advanced GBC, suggesting that HER2 mutation is important in GBC and that anti-HER2 drug therapy may be an option for the systemic treatment of GBC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.